Global Settlement for About 500 Androderm Cases by Actavis
Global Settlement for About 500 Androderm Cases by Actavis
Introduction
A case management order issued by Judge Matthew Kennelly on June 29, confirmed that Actavis has agreed to settle all Androderm lawsuits filed by men claiming they suffered a heart attack, stroke or other injuries as side effects of their testosterone replacement therapy (TRT) drug. As per the order, about 500 of the testosterone claims pending in the multidistrict litigation (MDL 2545; In Re: Testosterone Replacement Therapy Products Liability Litigation) involve Androderm.
Though no potential settlement order has been released, Judge Kennelly cited putting a stay on all Androderm claims against Actavis would allow parties to dedicate time and energy to finalize the agreement. The first bellwether trial date (August 6, 2018) for Androderm lawsuits has not been vacated yet.
Testosterone Replacement Therapy lawsuits are centralized before U.S. District Judge Matthew Kennelly in the Northern District of Illinois as a part of a federal multidistrict litigation (MDL No. 2545; In Re: Testosterone Replacement Therapy Products Liability Litigation).
Comments
Latest News
Cencora Directors Settle Opioid Oversight Case for $111M
Categories: Opioids
Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids…
Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients
Categories: Philips CPAP/BiPAP/ASV Sleep Apnea Machines
A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…
FDA Adds New Warnings on Long-Term Opioid Risks
Categories: Opioids
Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.
…